Comparison of Bipolar Disorder Patients with Healthy Controls in terms of Inflammatory Biomarkers

Year 2019, Volume: 5 Issue: 1, 1352 - 1360, 15.04.2019

Murat Eren Özen , Mehmet Hamdi Örüm , Mehmet Bertan Yılmaz , Aysun Kalenderoğlu

https://doi.org/10.30569/adiyamansaglik.481915

Cited By: 3

Abstract

Aim:
Inflammatory
changes occur in various episodes of Bipolar Disorder (BD) Type 1. These
changes can be considered as peripheral symptoms of the disorder. In this study,
we aimed to compare the BD patients in the manic, depressive and euthymic
period with respect to healthy control group and inflammatory biomarkers.

Method:
Interleukins
(IL) and tumor necrosis factor (TNF) values were measured and compared in 78
healthy controls and 108 patients with BD.

Results:
In the
subgroup of mania, the rate of psychiatric hospitalization was higher compared
to the subgroups of depression or subgroup (p=0.041). When the blood values of
peripheral biomarkers (IL-2, IL-4, IL-8, IL-10 and TNFα) were compared, there
was no statistically significant difference between the three subgroups of BD
(mania, depression and euthymic) and healthy control group (p>0.05).

Conclusions:
There was
no significant difference between the control group and the BD subgroups in
terms of IL and TNF levels. Further studies are needed to clarify the issue.

Keywords

Interleukin, tumor necrosis factor, bipolar disorder, inflammation

İnflamatuar Biyobelirteçler Açısından Bipolar Bozukluk Tip 1 Tanılı Hastaların Sağlıklı Kontrollerle Karşılaştırılması

Abstract

Amaç:
Bipolar
Bozukluk (BB) Tip 1’in çeşitli epizotlarında inflamatuar değişiklikler ortaya
çıkar. Bu değişiklikler bozukluğun periferik belirtileri olarak
değerlendirilebilir. Biz bu çalışmada, manik, depresif ve ötimik dönemdeki BB
hastalarını kendi aralarında ve sağlıklı kontrol grubu ile inflamatuar
biyobelirteçler açısından karşılaştırmayı amaçladık.

Yöntem:
İnterlökinler
(IL) ve tümör nekrozis faktör (TNF) değerleri 78 sağlıklı kontrol ve 108 BB
tanılı hastada ölçüldü ve karşılaştırıldı.

Bulgular:
Mani alt grubunda, depresyon veya ötimi alt gruplarına
göre daha fazla psikiyatrik yatış oranı görülmüştür (p=0.041). Periferik biyobelirteçlerin
(IL-2, IL-4, IL-8, IL-10 ve TNFα) kan değerlerini karşılaştırıldığında BB
(mani, depresyon ve ötimi)’nin 3 alt grubu ve kontrol grubu arasında
istatistiksel olarak anlamlı fark bulunmadı (p>0.05).

Sonuçlar:
IL ve TNF
seviyeleri açısında BB ve kontrol grubu arasında ve BB alt grupları arasında
farklılık yoktu. Örneklem sayısının artırıldığı çalışmalara ihtiyaç
duyulmaktadır.

Keywords

İnterlökin, tümör nekrozis faktör, bipolar bozukluk, inflamasyon

References

• 1. Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet 2016;387(10027):1561-72.
• 2. Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord 2016;18(5):440-50.
• 3. Castaño-Ramírez OM, Sepúlveda-Arias JC, Duica K, et al. Inflammatory Markers in the Staging of Bipolar Disorder: A Systematic Review of the Literature. Rev Colomb Psiquiatr 2018;47(2):119-28.
• 4. van den Ameele S, Coppens V, Schuermans J, et al. Neurotrophic and inflammatory markers in bipolar disorder: A prospective study. Psychoneuroendocrinology 2017;84:143-50.
• 5. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70(8):1078-90.
• 6. Knijff EM, Ruwhof C, de Wit HJ, et al. Monocyte-derived dendritic cells in bipolar disorder. Biol Psychiatry 2006;59(4):317-26.
• 7. Kapczinski F, Dias VV, Kauer-Sant’Anna M, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2009;33:1366-71.
• 8. Kapczinski F, Frey BN, Andreazza AC, et al. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 2008;30:243-5.
• 9. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 2010;13(10):1369-81.
• 10. Rapaport MH, Manji HK. The effects of lithium on ex vivo cytokine production. Biol Psychiatry 2001;50(3):217-24.
• 11. Parlakpinar H, Orum MH, Acet A. Caffeic acid phenethyl ester (CAPE) and myocardial ischemia reperfusion (MI/R) injury. Inonu University Journal of Health Sciences 2012;1:10-5.
• 12. Parlakpinar H, Orum MH, Acet A. Aminoguanidine and cardiovascular system. Inonu University Journal of Health Sciences 2012;2:9-14.
• 13. Parlakpinar H, Orum MH, Sagir M. Pathophysiology of myocardial ischemia reperfusion injury: A review. Medicine Science 2013;2(4):935-54.
• 14. Parlakpinar H, Orum MH. The antioxidant effect of melatonin on myocardial ischemia reperfusion injury in experimental studies. Medicine Science 2014;3(4):1766-80.
• 15. Orum MH, Kara MZ, Egilmez OB. Mean platelet volume and neutrophil to lymphocyte ratio as parameters to indicate the severity of suicide attempt, J Immunoassay Immunochem 2018;39(6):647-59.
• 16. Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010;15:784-6.
• 17. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 2014;171(12):1278-86.
• 18. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70(7):663-71.
• 19. Goldstein BI, Kemp DE, Soczynska JK MR. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70:1078-90.
• 20. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.
• 21. Akdemir A, Türkçapar MH, Örsel SD, et al. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001;42(2):161-5.
• 22. Karadağ F, Oral ET, Aran Yalçın F. ve ark. Young mani derecelendirme ölçeğinin Türkiye’de geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi 2001;13(2):107-14.
• 23. Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009;12:447-58.
• 24. Grande I, Magalhães PV, Chendo I, et al. Staging bipolar disorder: Clinical, biochemical, and functional correlates. Acta Psychiatr Scand 2014;129:437-44.
• 25. Kapczinski F, Fernandes BS, Kauer-Sant’Anna M, et al. The concept of staging in bipolar disorder: The role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatr 2009;21:272-4.
• 26. Modabbernia A, Taslimi S, Brietzke E, et al. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol Psychiatry 2013;74:15-25.
• 27. Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007;104:91-5.
• 28. Bai YM, Su TP, Tsai SJ, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord 2014;166:187-92.
• 29. Li H, Hong W, Zhang C, et al. IL-23 and TGF-1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord 2015;174:361-6.